

Soheil Meshinchi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5399590/publications.pdf>

Version: 2024-02-01

36
papers

2,807
citations

471509

17
h-index

477307

29
g-index

38
all docs

38
docs citations

38
times ranked

4381
citing authors

#	ARTICLE	IF	CITATIONS
1	Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours. <i>Nature</i> , 2018, 555, 371-376.	27.8	649
2	Gemtuzumab Ozogamicin in Children and Adolescents With De Novo Acute Myeloid Leukemia Improves Event-Free Survival by Reducing Relapse Risk: Results From the Randomized Phase III Children's Oncology Group Trial AAML0531. <i>Journal of Clinical Oncology</i> , 2014, 32, 3021-3032.	1.6	360
3	Clinical implications of FLT3 mutations in pediatric AML. <i>Blood</i> , 2006, 108, 3654-3661.	1.4	355
4	Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group. <i>Blood</i> , 2012, 120, 1581-1588.	1.4	256
5	Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group. <i>Blood</i> , 2009, 113, 6558-6566.	1.4	166
6	AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia. <i>Cancer</i> , 2012, 118, 761-769.	4.1	157
7	Genomic Profiling of Pediatric Acute Myeloid Leukemia Reveals a Changing Mutational Landscape from Disease Diagnosis to Relapse. <i>Cancer Research</i> , 2016, 76, 2197-2205.	0.9	133
8	CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children's Oncology Group Trial AAML0531. <i>Journal of Clinical Oncology</i> , 2017, 35, 2674-2682.	1.6	120
9	CD33 Expression and Its Association With Gemtuzumab Ozogamicin Response: Results From the Randomized Phase III Children's Oncology Group Trial AAML0531. <i>Journal of Clinical Oncology</i> , 2016, 34, 747-755.	1.6	116
10	Leukemic mutations in the methylation-associated genes <i>DNMT3A</i> and <i>IDH2</i> are rare events in pediatric AML: A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2011, 57, 204-209.	1.5	109
11	NUP98/NSD1 and FLT3/ITD coexpression is more prevalent in younger AML patients and leads to induction failure: a COG and SWOG report. <i>Blood</i> , 2014, 124, 2400-2407.	1.4	99
12	Arsenic Trioxide Consolidation Allows Anthracycline Dose Reduction for Pediatric Patients With Acute Promyelocytic Leukemia: Report From the Children's Oncology Group Phase III Historically Controlled Trial AAML0631. <i>Journal of Clinical Oncology</i> , 2017, 35, 3021-3029.	1.6	62
13	CSF3R mutations have a high degree of overlap with CEBPA mutations in pediatric AML. <i>Blood</i> , 2016, 127, 3094-3098.	1.4	49
14	Genomics of primary chemoresistance and remission induction failure in paediatric and adult acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2017, 176, 86-91.	2.5	29
15	Distinct age-associated molecular profiles in acute myeloid leukemia defined by comprehensive clinical genomic profiling. <i>Oncotarget</i> , 2018, 9, 26417-26430.	1.8	25
16	Phenotype in combination with genotype improves outcome prediction in acute myeloid leukemia: a report from Children's Oncology Group protocol AAML0531. <i>Haematologica</i> , 2017, 102, 2058-2068.	3.5	22
17	Morphologic remission status is limited compared to \hat{P} N flow cytometry: a Children's Oncology Group AAML0531 report. <i>Blood Advances</i> , 2020, 4, 5050-5061.	5.2	21
18	Genomic architecture and treatment outcome in pediatric acute myeloid leukemia: a Children's Oncology Group report. <i>Blood</i> , 2017, 129, 3051-3058.	1.4	19

#	ARTICLE	IF	CITATIONS
19	Shorter Remission Telomere Length Predicts Delayed Neutrophil Recovery After Acute Myeloid Leukemia Therapy: A Report From the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2016, 34, 3766-3772.	1.6	17
20	Structural Variants Involving MLLT10/AF10 Are Associated with Adverse Outcome in AML Regardless of the Partner Gene - a COG/Tpaml Study. <i>Blood</i> , 2019, 134, 461-461.	1.4	12
21	Transcriptome Profiling of Glycosylation Genes Defines Correlation with E-Selectin Ligand Expression and Clinical Outcome in AML. <i>Blood</i> , 2019, 134, 3772-3772.	1.4	7
22	ETS Family Transcription Factor Fusions in Childhood AML: Distinct Expression Networks and Clinical Implications. <i>Blood</i> , 2021, 138, 2356-2356.	1.4	4
23	Concordance of copy number alterations using a common analytic pipeline for genome-wide analysis of Illumina and Affymetrix genotyping data: a report from the Children's Oncology Group. <i>Cancer Genetics</i> , 2015, 208, 408-413.	0.4	3
24	Hierarchical Clustering of Immunophenotypic Cell Surface Antigen Expression Identifies Clinically Meaningful Cohorts in Childhood AML: A Report from the Children's Oncology Group Protocol AAML0531. <i>Blood</i> , 2015, 126, 561-561.	1.4	3
25	Therapeutic Targeting of CD74 with STRO-001 Antibody-Drug Conjugate in AML and ALL. <i>Blood</i> , 2021, 138, 509-509.	1.4	3
26	Targeting PRAME with TCR-Mimic CAR T Cells in AML. <i>Blood</i> , 2021, 138, 733-733.	1.4	2
27	Single Cell Network Profiling (SCNP)-Based Classifier to Predict Response to Induction Therapy in Pediatric Patients with De Novo Acute Myeloid Leukemia (AML): Validation Study Results., <i>Blood</i> , 2011, 118, 3544-3544.	1.4	1
28	Down Syndrome AML Is Unique in Phenotype Both at Diagnosis and in Post Chemotherapy Regeneration. <i>Blood</i> , 2016, 128, 1687-1687.	1.4	1
29	Targeting FOLR1 in High-Risk CBF2AT3-GLIS2 AML with Stro-002 FOLR1-Directed Antibody-Drug Conjugate. <i>Blood</i> , 2021, 138, 209-209.	1.4	1
30	Newly Diagnosed Childhood AML Patients Treated with Bortezomib Show Superior Survival If CD74 Is Expressed: A Report of 991 Patients from the Children's Oncology Group AAML1031 Protocol. <i>Blood</i> , 2020, 136, 39-39.	1.4	1
31	The Transcriptomic Landscape of NUP98-Rearranged Pediatric Acute Myeloid Leukemia. <i>Blood</i> , 2020, 136, 36-37.	1.4	1
32	The Prognostic Effect of High WT1 Gene Expression in Pediatric AML Depends on WT1 SNP rs16754 Status: A Report From the Children's Oncology Group (COG). <i>Blood</i> , 2011, 118, 1444-1444.	1.4	0
33	Constitutional Telomerase-Associated Gene Variants In Pediatric Acute Myeloid Leukemia (AML) and In Association With Chemotherapy-Related Toxicities. <i>Blood</i> , 2013, 122, 1310-1310.	1.4	0
34	Immunotherapeutic Targeting of TSLPR with Chimeric Antigen Receptor T Cells in AML. <i>Blood</i> , 2021, 138, 2789-2789.	1.4	0
35	Donor Bone Marrow Derived Macrophage Engraftment into the Central Nervous System of Allogeneic Transplant Patients. <i>Blood</i> , 2021, 138, 645-645.	1.4	0
36	EZH2-Mediated MHC Class II Silencing Drives Immune Evasion in AML with t(16;21) (<i>FUS-ERG</i>). <i>Blood</i> , 2021, 138, 374-374.	1.4	0